Login
Subscribe
Take a FREE Trial
About Us
Contact us
RSS
22 May 2013
Search
The Pharma Letter
Home
7 Day Premium Trial
Pharmaceuticals
Biotechnology
Generics
Events
Companies
Drugs
Subscribe
HyQ Articles
News briefs: setbacks for B-MS hep C drug; Baxter's HyQ
2 August 2012
Halozyme plunges as FDA call for more data on HyQ BLA
17 April 2012
Showing 1-2 of 2 articles
1
Hot Topics
Most Read
Is failure to adopt business process management putting the pharma industry at risk?
Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
New Zealand declines Alexion's funding application for Solaris
AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
Is failure to adopt business process management putting the pharma industry at risk?
Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
New Zealand declines Alexion's funding application for Solaris
AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations